[
  {
    "ts": null,
    "headline": "How Positive Phase 2 Results for Novel Antibodies at Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story",
    "summary": "In recent days, Regeneron Pharmaceuticals announced detailed positive Phase 2 trial results for two novel factor XI antibodies aimed at preventing blood clotting in total knee replacement surgery patients. This progress highlights Regeneron's continued expansion into new therapeutic areas, potentially strengthening the company's position in advancing specialty biologics for unmet clinical needs. We'll explore how these encouraging trial outcomes for the investigational factor XI antibodies...",
    "url": "https://finnhub.io/api/news?id=852289b6ccbfcad08e2362d8a5a2481989b1d425faf33d271b2073537a34c78d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762647762,
      "headline": "How Positive Phase 2 Results for Novel Antibodies at Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story",
      "id": 137384668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "In recent days, Regeneron Pharmaceuticals announced detailed positive Phase 2 trial results for two novel factor XI antibodies aimed at preventing blood clotting in total knee replacement surgery patients. This progress highlights Regeneron's continued expansion into new therapeutic areas, potentially strengthening the company's position in advancing specialty biologics for unmet clinical needs. We'll explore how these encouraging trial outcomes for the investigational factor XI antibodies...",
      "url": "https://finnhub.io/api/news?id=852289b6ccbfcad08e2362d8a5a2481989b1d425faf33d271b2073537a34c78d"
    }
  }
]